Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials

Cancer Treatment Reviews

Volumn 33, Issue 5, 2007, Pages 474-483

  Estévez, Laura G ^a   Muñoz, Montserrat ^b   Alvarez, Isabel ^c   Fernández, Yolanda ^d   García Mata, Jesús ^e   Ruiz Borrego, Manuel ^f   Tusquets, Ignasi ^g   Seguí, Miguel Ángel ^h   Rodríguez Lescure, Alvaro ⁱ   Adrover, Encarna ^j   Lluch, Ana ^k  

^a HM Hospitales Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e Instituto de Investigación Biomédica Ourense Vigo Pontevedra   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL DE SABADELL   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Adjuvant treatment; Breast cancer; Docetaxel; Paclitaxel; Randomized trials; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HEART DISEASE; HUMAN; LOW DRUG DOSE; META ANALYSIS; MOTOR NEURON DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; STOMATITIS; TREATMENT DURATION;

ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 34548335196     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.04.006     Document Type: Review

References (45)

1. Bonadonna G., and Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304 1 (1981) 10-15
2. Martin M., Villar A., Sole-Calvo A., et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14 6 (2003) 833-842
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
4. Rivera E., Holmes F.A., Frye D., et al. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89 11 (2000) 2195-2201
5. Holmes F.A., Walters R.S., Theriault R.L., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83 24 (1991) 1797-1805
6. Ravdin P.M., Burris III H.A., Cook G., et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13 12 (1995) 2879-2885
7. Valero V., Holmes F.A., Walters R.S., et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13 12 (1995) 2886-2894
8. Nabholtz J.M., Thuerlimann B., Bezwoda W.R., et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park) 11 8 Suppl 8 (1997) 25-30
9. Bonneterre J., Spielman M., Guastalla J.P., et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35 10 (1999) 1431-1439
10. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 8 (1999) 2341-2354
11. Sledge G.W., Neuberg D., Bernardo P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 4 (2003) 588-592
12. Mackey J.R., Paterson A., Dirix L.Y., et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21 (2002) 137
13. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 6 (2003) 968-975
14. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19 6 (2001) 1707-1715
15. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20 14 (2002) 3114-3121
16. Luck H., Thomssen C., Untch M., et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the ago breast cancer group. Proc Am Soc Clin Oncol 19 (2000) 280
17. ® (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20 (2001) 84
18. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
19. Roche H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24 36 (2006) 5664-5671
20. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
21. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23 16 (2005) 3686-3696
22. Martín M., Rodríguez-Lescure A., Ruiz A., et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node-positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 trial. Breast Cancer Symposium (2005) 39
23. Jones S.E., Savin M.A., Holmes F.A., et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24 34 (2006) 5381-5387
24. Martin M., Lluch A., Segui M.A., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17 8 (2006) 1205-1212
25. Goldstein L., O'Neill A., Sparano J., et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc Am Soc Clin Oncol 23 (2005) 512
26. Hutchins L.F., Green S.J., Ravdin P.M., et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of intergroup protocol INT-0102. J Clin Oncol 23 33 (2005) 8313-8321
27. Fisher B., Brown A.M., Dimitrov N.V., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8 9 (1990) 1483-1496
28. Brain E.G., Bachelot T., Serin D., et al. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. Jama 293 19 (2005) 2367-2371
29. Alba E., Martin M., Ramos M., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22 13 (2004) 2587-2593
30. Fumoleau P., Kerbrat P., Romestaing P., et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21 2 (2003) 298-305
31. Bonneterre J., Roche H., Kerbrat P., et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23 12 (2005) 2686-2693
32. Sartor C.I., Peterson B.L., Woolf S., et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol 23 1 (2005) 30-40
33. Fisher B., Anderson S., Wickerham D.L., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15 5 (1997) 1858-1869
34. Albain K.S., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21 (2002) 143
35. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
36. Trent J.C., Valero V., Booser D.J., et al. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9 7 (2003) 2426-2434
37. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 24 (2005) 5542-5551
38. Seidman A.D., Berry D., Cirrincione C., et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 22 (2004) 512
39. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 25 (2005) 5983-5992
40. Sparano J.A., Wang M., Martino S., et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Symposium (2005) 48
41. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
42. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6 Suppl 3 (2001) 30-35
43. Hudis C., Citron M., Berry D., et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Symposium (2005) 41
44. Eiermann W., Pienkowski T., Crown J., et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Symposium (2005) 1069
45. Crown J.P., Francis P., Di Leo A., et al. Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 trial at 5 years median follow-up (MFU). Proc Am Soc Clin Oncol 24 (2006) 519